Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Fendrich, Gabriele"'
Autor:
Zhang, Jianming, Adrián, Francisco J., Jahnke, Wolfgang, Cowan-Jacob, Sandra W., Li, Allen G., Iacob, Roxana E., Sim, Taebo, Powers, John, Dierks, Christine, Sun, Fangxian, Guo, Gui-Rong, Ding, Qiang, Okram, Barun, Choi, Yongmun, Wojciechowski, Amy, Deng, Xianming, Liu, Guoxun, Fendrich, Gabriele, Strauss, Andre, Vajpai, Navratna, Grzesiek, Stephan, Tuntland, Tove, Liu, Yi, Bursulaya, Badry, Azam, Mohammad, Manley, Paul W., Engen, John R., Daley, George Q., Warmuth, Markus, Gray, Nathanael S.
In an effort to find new pharmacological modalities to overcome resistance to ATP-site inhibitors of Bcr-Abl, we recently reported the discovery of GNF-2, a selective allosteric Bcr-Abl inhibitor. Here, using solution NMR, X-ray crystallography, muta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6e1dfcc45e2a8dfc98aa2e9f6b40cd1f
https://europepmc.org/articles/PMC2901986/
https://europepmc.org/articles/PMC2901986/
Autor:
Griffin D. James, Fendrich Gabriele, Manley W. Paul, Cowan-Jacob Sandra, Furet Pascal, Fabbro Doriano, Weisberg Ellen, Goutte Gerard, Juergen Mestan, Kempf Dominique, Gaugler Markus
Publikováno v:
Blood. 104:1978-1978
Imatinib mesylate (Gleevec®, Novartis Pharma AG), an inhibitor of the c-Abl/Bcr-Abl, c-Kit, and PDGFR kinases, is an effective therapy for CML, GIST and HES. However, advanced stage CML and Ph+ ALL patients frequently relapse due to the development